EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study

Raffaele De Caterina iD, Eva-Maria Fronk, Joana Nunes iD, Mathias Lamparter, Paulus Kirchhof, Carmine Zoccali iD, ETNA‐AF Europe Investigators

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70268 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Raffaele De Caterina und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pisa and Pisa University Hospital, Pisa, Italy. Hauptthemen laut MEDLINE: Thiazoles, Pyridines, Stroke, Renal Insufficiency, Chronic. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐vitamin K oral anticoagulants, like edoxaban, are essential in managing atrial fibrillation (AF). The impact of renal function on edoxaban dosages in real‐world settings remains unclear. This 4‐year ETNA‐AF‐Europe study follow‐up analysis investigated how chronic kidney disease (CKD) stages affect the safety and effectiveness of usual edoxaban doses.

Methods

ETNA‐AF‐Europe (NCT02944019) was an observational study conducted from 2016 to 2022 across 776 centres in 10 European countries. Hazard ratios (HR) and annualized event rates were calculated for all‐cause death, cardiovascular (CV) death, stroke and bleeding events for the overall population and participants stratified by dose (30/60 mg) and CKD stages at baseline.

Results

Of the 13,164 participants in the full analysis set, 9114 participants with CKD (Stage 1, n = 2064; Stage 2, n = 4855; Stage 3, n = 1985; Stage 4, n = 135; missing, n = 75) received label‐recommended edoxaban doses. Compared with CKD Stage 1, higher CKD stages were associated with increased risks for stroke (Stage 3: HR [95% CI]: 1.889 [1.240–2.878], p = 0.003) and CV death (HR [95% CI]; Stage 4: 14.450 [8.270–25.247], Stage 3: 4.672 [3.312–6.969], Stage 2: 2.066 [1.394–3.062], all p < 0.001). All‐cause death followed a similar trend. After adjusting for age, sex, body weight, CHA 2 DS 2 ‐VASc and modified HAS‐BLED scores, most bleeding and effectiveness outcomes showed no nominally significant differences across CKD stages.

Conclusions

Edoxaban in patients with AF is effective and well tolerated across CKD stages and appropriate label dosing can offset the risk from renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesPyridinesStrokeRenal Insufficiency, ChronicAtrial FibrillationFactor Xa InhibitorsHumansFemaleMaleEuropeAgedHemorrhageMiddle AgedCardiovascular DiseasesCause of DeathTreatment OutcomeGlomerular Filtration RateProportional Hazards Models

Stichwörter der Autor:innen

atrial fibrillationchronic kidney diseaseedoxabannon‐vitamin K oral anticoagulantstroke prevention

Substanzen

ThiazolesedoxabanPyridinesFactor Xa Inhibitors

Autor:innen und Institutionen

  • University of Pisa and Pisa University Hospital, Pisa, Italy.
  • Daiichi Sankyo Europe GmbH, Munich, Germany.
  • Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
  • Institute of Molecular Biology and Genetics, Ariano Irpino, Italy.
  • Association for Hypertension, Nephrology, and Kidney Transplant (IPNET), Nephrology, Great Metropolitan Hospital, Reggio Calabria, Italy.

ORCID-Profile: Raffaele De Caterina, Joana Nunes, Carmine Zoccali

Förderung

  • Daiichi Sankyo Europe GmbH
  • Daiichi Sankyo Europe

Zitieren

APA

De Caterina, R., Fronk, E. M., Nunes, J., Lamparter, M., Kirchhof, P., Zoccali, C., & ETNA‐AF Europe Investigators (2026). Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70268

Vancouver

De Caterina R, Fronk EM, Nunes J, Lamparter M, Kirchhof P, Zoccali C, et al. Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70268

BibTeX
@article{DeCaterina2026,
  author = {De Caterina, Raffaele and Fronk, Eva-Maria and Nunes, Joana and Lamparter, Mathias and Kirchhof, Paulus and Zoccali, Carmine and ETNA‐AF Europe Investigators, ETNA‐AF Europe Investigators},
  title = {Renal Function and 4‐Year Outcomes in Edoxaban‐Treated Patients: A Sub‐Analysis From the ETNA ‐ AF Europe Study},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70268}
}
Kostenlos starten →